相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop et al.
BLOOD (2010)
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited
Abhinav Deol et al.
CANCER TREATMENT REVIEWS (2010)
Application of the Fc fusion format to generate tag-free bi-specific diabodies
Ryutaro Asano et al.
FEBS JOURNAL (2010)
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
Ralf Lutterbuese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome
N. Grinshtein et al.
CANCER GENE THERAPY (2009)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)
Mohamed L. Salem et al.
JOURNAL OF IMMUNOLOGY (2009)
A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells
T. Otz et al.
LEUKEMIA (2009)
Second-Generation Anti-Carcinoembryonic Antigen Designer T Cells Resist Activation-induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation
Peter C. R. Emtage et al.
CLINICAL CANCER RESEARCH (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors
Matthew G. Fury et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
Klaus Brischwein et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3):: a phase I study
Martin Sebastian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells
Ryutaro Asano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
Alexander Burges et al.
CLINICAL CANCER RESEARCH (2007)
Induction of adaptive anti-HER2/neu immune responses in a phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194):: A trial coordinated by the Eastern Cooperative Oncology Group
Hossein Borghaei et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation
Daniel H. Fowler et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
Philipp Kiewe et al.
CLINICAL CANCER RESEARCH (2006)
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
EA Rossi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study
JK Chan et al.
CLINICAL CANCER RESEARCH (2006)
Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation
RC Grabert et al.
CLINICAL CANCER RESEARCH (2006)
Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model
U Reusch et al.
CLINICAL CANCER RESEARCH (2006)
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing
LX Wang et al.
CANCER RESEARCH (2005)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct
B Schlereth et al.
CANCER RESEARCH (2005)
T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro
JM Gall et al.
EXPERIMENTAL HEMATOLOGY (2005)
Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1
LJN Cooper et al.
BLOOD (2005)
Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy
QZ Ma et al.
PROSTATE (2004)
A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing
L Grosse-Hovest et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct
T Dreier et al.
JOURNAL OF IMMUNOLOGY (2003)
Bispecific antibody conjugates in therapeutics
Y Cao et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Targeting tumours with genetically enhanced T lymphocytes
M Sadelain et al.
NATURE REVIEWS CANCER (2003)
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma
P Borchmann et al.
BLOOD (2002)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
T Dreier et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Antigen-dependent release of IFN-γ by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis
A Müllbacher et al.
JOURNAL OF IMMUNOLOGY (2002)
Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells - Phase I clinical trial
LG Lum et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Humanization and characterization of the anti-HLA-DR antibody 1D10
SA Kostelny et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+advanced prostate cancer
ND James et al.
BRITISH JOURNAL OF CANCER (2001)
Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (αEpCAM x αCD3)
R Riesenberg et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2001)
Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity
AM McCall et al.
JOURNAL OF IMMUNOLOGY (2001)
Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors
M Sen et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
TCR stimulation protects CD8(+) T cells from CD95 mediated apoptosis
M Karas et al.
HUMAN IMMUNOLOGY (2001)
Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu
T Schwaab et al.
JOURNAL OF IMMUNOTHERAPY (2001)
分享论文
